STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Phase 3positivepersonalized mRNA cancer vaccinePositive
AI Analysis
Summary
Moderna and Merck announced positive Phase 3 results for a personalized mRNA cancer vaccine in melanoma, demonstrating a potentially powerful new oncology approach.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
mRNA cancer vaccine succeeded in late-stage melanoma trial
Importance:8/10
Sentiment:
0.85
oncologymRNApersonalized medicinemelanomacancer vaccinelate-stage trial
Read the original article
Published by STAT News on August 19, 2026 10:45 AM